|
Patent landscape, scope, and claims: |
United States Patent 8,993,640: Scope, Claim Architecture, and Landscape
United States Patent 8,993,640 is built around (i) a core compound defined by a formula in Claim 1, (ii) polymorphic/crystalline forms of that compound identified by Cu Kα X-ray powder diffraction (XRPD) peak patterns and thermal properties (Tg, DSC endotherms), (iii) solvates including an acetonitrile hemisolvate, and (iv) a pharmaceutical composition and method of treatment focused on inflammation and oxidative stress, with explicit emphasis on radiation-induced oral mucositis and radiation-induced dermatitis.
The claims are tightly constrained by measurement-based definitions (XRPD patterns, Tg, DSC) and by use-based language (indications and treatment timing). This claim design narrows what can infringe compared with broad “compound-only” patents, but it increases enforceability against products that market and manufacture specific solid forms.
What is the patent’s claim scope in US 8,993,640?
1) Core compound coverage (Claim 1)
- Claim 1 covers:
- “A compound of the formula … or a pharmaceutically acceptable salt thereof.”
- Practical scope:
- Any product that is the exact chemical entity of the claimed formula (including acceptable salts) can fall within Claim 1, regardless of solid form, unless separated by later dependent claim requirements.
2) Solid-state form coverage (Claims 2-18)
Claims 2 to 18 create layered protection for multiple polymorphs and solvates, each defined by XRPD peak criteria and often confirmed with thermal transitions.
Polymorph defined by halo peak (Claims 2-7)
-
Claim 2: a polymorphic form with XRPD (Cu Kα):
- “halo peak at about 14° 2θ”
-
Claim 3: polymorph of Claim 2 with an additional:
- “shoulder peak at about 8° 2θ”
-
Claims 4 and 7: link to figures:
- “as shown in FIG. 59” (XRPD pattern)
- “DSC curve as shown in FIG. 62”
-
Claims 5-6: thermal constraint:
- Tg from 150°C to 155°C
- DSC endotherm centered from 150°C to 155°C
This is a classic measurement-defined polymorph claim: it does not say “any polymorph having similar behavior,” it points to specific diffraction features and thermal windows.
Solvate-defined forms (Claims 8-18)
Claims 8, 10, and 12 define solvates by XRPD sets of significant peaks, then dependent claims reference the figure patterns. Claims 14-16 further add thermal properties for the acetonitrile hemisolvate.
-
Claim 8: solvate with significant XRPD peaks at about:
- 5.6, 7.0, 10.6, 12.7, 14.6° 2θ
-
Claim 9: XRPD “as shown in FIG. 75, top pattern.”
-
Claim 10: solvate with significant peaks at about:
- 7.0, 7.8, 8.6, 11.9, 13.9 (double peak), 14.2, 16.0° 2θ
-
Claim 11: XRPD “as shown in FIG. 75, second pattern from top.”
-
Claim 12: acetonitrile hemisolvate with significant peaks at about:
- 7.5, 11.4, 15.6, 16.6° 2θ
-
Claim 13: XRPD “as shown in FIG. 75, second pattern from bottom.”
-
Claims 14-16: thermal constraints for the acetonitrile hemisolvate:
- Claim 14: Tg about 196°C
- Claim 15: DSC endotherm centered about 196°C
- Claim 16: DSC curve “as shown in FIG. 116.”
-
Claim 17: another solvate with significant peaks at about:
- 6.8, 9.3, 9.5, 10.5, 13.6, 15.6° 2θ
-
Claim 18: XRPD “as shown in FIG. 75, bottom pattern.”
3) Composition and use claims (Claims 19-23)
Composition (Claim 19)
- Claim 19: a pharmaceutical composition comprising:
- an active ingredient consisting of a compound of Claim 1
- plus a pharmaceutically acceptable carrier
This claim ties formulation coverage to the core compound of Claim 1 rather than to the specific polymorph/solvate forms in Claims 2-18. In enforcement, the accused product must use the Claim 1 compound (as active), but the formulation itself is described generically.
Methods (Claims 20-23)
- Claim 20: treating conditions associated with inflammation or oxidative stress, selected from:
- prostate cancer, dermatitis, sepsis, pulmonary inflammation, pulmonary fibrosis, COPD, asthma, mucositis, ocular inflammation
- Claim 21: dermatitis is radiation-induced dermatitis
- Claim 22: mucositis is radiation-induced mucositis resulting from:
- radiation therapy or chemotherapy
- Claim 23: a specific timing and use method:
- reducing duration and/or severity of radiation-induced oral mucositis or radiation-induced dermatitis
- administering the composition prior to and/or after acute radiation treatment
This last claim narrows to the clinical prophylaxis/post-exposure window, which can matter in product instructions, clinical protocols, and labeling.
How do the claims enforce against products? (Practical infringement map)
A) Products containing the claimed compound
- A drug product containing the exact active chemical entity of Claim 1 (or an acceptable salt) is within the outer compound scope, and can also satisfy Claim 19 if formulated with a pharmaceutically acceptable carrier.
B) Products selling specific solid forms
- Products that market or use particular polymorph/solvate solids can fall under Claims 2-18 if their XRPD and thermal signatures match.
- The most enforceable claim elements are the XRPD peak lists and the Tg/DSC windows because solid-state characterization is measurable and can be repeated across lots.
C) Products positioned for radiation-induced indications
- Even if the active ingredient matches Claim 1, method infringement depends on indication and treatment instructions:
- Radiation-induced dermatitis and radiation-induced oral mucositis language appears explicitly in Claims 21-23.
- If a product is marketed for non-radiation inflammation uses only, Claim 23’s specialized timing language becomes less likely to be implicated.
What does the “solid form” claim strategy do to the patent’s breadth?
Polymorph claims are narrow by diffraction features
- Claim 2 is defined by a halo peak around 14° 2θ (Cu Kα).
- Claim 3 adds a shoulder at about 8° 2θ.
- Claims 4 and 7 tie to specific figures (FIG. 59 and FIG. 62), which typically function as interpretive anchors for what the patentee considers to be the compliant pattern.
- Claims 5-6 constrain by:
- Tg 150-155°C
- DSC endotherm centered 150-155°C
Solvate claims are narrower by peak sets
- Claims 8, 10, and 17 use multiple peak positions, which is harder for competitors to avoid while using the same crystallization process.
- Claim 12 is explicitly an acetonitrile hemisolvate, adding process/handling relevance because hemisolvates can transform under drying or humidity.
Thermal parameters add an extra “knock-out” variable
- Claim 14-16 add thermal signature to Claim 12’s acetonitrile hemisolvate:
- Tg about 196°C
- DSC endotherm centered about 196°C
- A competitor can potentially change the solid form by converting to a different hydrate/solvate form or by drying to remove residual solvent. If the product changes to a non-hemisolvate form, Claims 12-16 can fall away even if Claim 1 is still met.
Claim-by-claim scope summary table (core elements)
| Claim |
Category |
Key defining limitations |
| 1 |
Compound |
Chemical formula; pharmaceutically acceptable salts |
| 2 |
Polymorph |
XRPD (Cu Kα) includes halo peak about 14° 2θ |
| 3 |
Polymorph (dependent) |
XRPD includes shoulder about 8° 2θ |
| 4 |
Polymorph (dependent) |
XRPD “as shown in FIG. 59” |
| 5 |
Polymorph (dependent) |
Tg about 150-155°C |
| 6 |
Polymorph (dependent) |
DSC endotherm centered about 150-155°C |
| 7 |
Polymorph (dependent) |
DSC “as shown in FIG. 62” |
| 8 |
Solvate |
XRPD peaks about 5.6, 7.0, 10.6, 12.7, 14.6° |
| 9 |
Solvate (dependent) |
XRPD “as shown in FIG. 75, top pattern” |
| 10 |
Solvate |
XRPD peaks about 7.0, 7.8, 8.6, 11.9, 13.9 (double), 14.2, 16.0° |
| 11 |
Solvate (dependent) |
XRPD “as shown in FIG. 75, second from top” |
| 12 |
Solvate (named) |
Acetonitrile hemisolvate; XRPD peaks about 7.5, 11.4, 15.6, 16.6° |
| 13 |
Solvate (dependent) |
XRPD “as shown in FIG. 75, second from bottom” |
| 14 |
Solvate (dependent) |
Tg about 196°C |
| 15 |
Solvate (dependent) |
DSC endotherm centered about 196°C |
| 16 |
Solvate (dependent) |
DSC “as shown in FIG. 116” |
| 17 |
Solvate |
XRPD peaks about 6.8, 9.3, 9.5, 10.5, 13.6, 15.6° |
| 18 |
Solvate (dependent) |
XRPD “as shown in FIG. 75, bottom pattern” |
| 19 |
Composition |
Active ingredient is compound of Claim 1 + pharmaceutically acceptable carrier |
| 20 |
Method |
Inflammation/oxidative stress conditions incl. prostate cancer, dermatitis, sepsis, lung inflammation/fibrosis, COPD, asthma, mucositis, ocular inflammation |
| 21 |
Method (dependent) |
Dermatitis is radiation-induced |
| 22 |
Method (dependent) |
Mucositis is radiation therapy/chemo induced |
| 23 |
Method (dependent) |
Reduce duration/severity of radiation-induced oral mucositis or dermatitis; administer prior to and/or after acute radiation treatment |
What is the patent landscape around US 8,993,640?
Landscape constraints from the provided record
A real “patent landscape” requires bibliographic and citation data: filing chain, assignee, application publication numbers, family members, forward citations, and competing solid-form or use patents for the same active. None of those inputs are provided here beyond the asserted claim text.
Per operating constraints, no incomplete landscape can be produced. The only defensible “landscape” statement based on the claims themselves is that the patent’s competitive pressure is concentrated in:
- solid-form freedom-to-operate (XRPD-defined polymorphs/solvates, especially acetonitrile hemisolvate),
- radiation-induced oral mucositis/dermatitis labeling and protocols, and
- formulation that uses the Claim 1 compound.
What to treat as the competitive threat vectors
Even without citation mapping, the claim design indicates the infringement-prone scenarios:
-
Same active, same solid form
- If a competitor’s API solid matches one of the XRPD-defined forms, Claims 2-18 are directly implicated.
-
Same active, generic “compound” formulation
- If they use Claim 1 compound in a formulation, Claim 19 becomes a direct line of attack.
-
Same active, radiation-induced indication
- If their product claims or is used in a way that matches Claims 20-23, method exposure follows, especially for prophylaxis/post-exposure administration around acute radiation.
Key Takeaways
- US 8,993,640 is strongest where the accused product matches the specific crystalline/solvate signatures: XRPD peak positions (Cu Kα) and thermal metrics (Tg and DSC endotherms).
- The acetonitrile hemisolvate is the most structurally “closed” concept in the claim set: it is explicitly named (Claim 12) and reinforced with Tg about 196°C and a DSC endotherm centered about 196°C (Claims 14-15).
- Composition coverage (Claim 19) ties formulation infringement to the core compound of Claim 1.
- Method claims (Claims 21-23) create a clear litigation target for products positioned for radiation-induced dermatitis and radiation-induced oral mucositis, with timing constraints around acute radiation treatment.
FAQs
-
Which claims most directly target solid-form copies?
Claims 2-18, because they define polymorphs/solvates using XRPD (Cu Kα) peak positions and, for key forms, Tg and DSC endotherms.
-
Does Claim 19 require a specific polymorph or solvate?
Claim 19 requires the active ingredient to be the compound of Claim 1; it does not explicitly require one of the polymorph/solvate XRPD-defined forms.
-
Why is the acetonitrile hemisolvate important in this patent?
Claim 12 explicitly defines the acetonitrile hemisolvate by XRPD peak positions, then Claims 14-16 add Tg about 196°C and a matching DSC endotherm.
-
What indications are expressly included for method infringement?
Claims include inflammation/oxidative stress conditions, including dermatitis and mucositis, and Claim 21-22 specify radiation-induced dermatitis and radiation therapy/chemotherapy induced mucositis.
-
Does Claim 23 require dosing before radiation?
Claim 23 requires administering “prior to and/or after said acute radiation treatment,” which covers both prophylactic and post-exposure regimens around acute radiation.
References
[1] United States Patent US 8,993,640. Claims as provided in the prompt (Claims 1-23).
More… ↓
⤷ Start Trial
|
